retatrutide clinical trial results 2024 2025 press release Eli Lilly just released impressive study for retatrutide, an investigational weight loss drug that targets three hormones—and may deliver more weight loss than current GLP-1s. See link below ⬇️ October 27, 2025: U.K. regulators

The company plans to resubmit the application for neffy in the first half of next year and anticipates another FDA action date in the second half of 2024

[DOI] [PubMed] [Google Scholar] 85

10.1016/S0140-6736(19)31149-3 9

Scientifically-Proven Formula Our natural, GLP-1 activating formula was developed and refined over the past 8 yearsincluding two clinical trials and over 100 studies that support the safety and efficacy of the ingredients in Pivit

PlexusDx Weight Management Protocols are billed monthly with no membership fee and no multi-month prepay lock-in a patient can stop the protocol after any month without forfeiting prepaid future months, and the Precision Peptide Genetic Test is a one-time $298 charge (or $99 add-on) rather than a recurring fee